MC2 Therapeutics is a privately held company that is revolutionizing the way we treat psoriasis and other autoimmune and chronic inflammatory skin conditions. With their groundbreaking PAD™️ Technology, they have developed a prescription cream that not only effectively treats the symptoms of psoriasis but also significantly improves patient satisfaction. Driven by a deep understanding of skin biology and the pathophysiology across various disease segments, MC2 Therapeutics is committed to developing novel treatment paradigms that address the complex challenges faced by individuals with skin conditions.

Their cutting-edge research and innovative approach have led to the development of drug candidates for conditions such as Chronic Kidney Disease associated Pruritus and Lichen Sclerosus. With their proprietary formulation and drug delivery system, PAD Technology™, MC2 Therapeutics has set a new standard in topical therapy. Their flagship product, Wynzora® Cream, has been widely acclaimed in the US and EU for its effectiveness in treating plaque psoriasis in adults.

With a high-performance culture and a focus on expertise, MC2 Therapeutics aims to continue expanding their business and establishing themselves as a fully integrated biopharmaceutical company. They are dedicated to improving the lives of individuals with skin conditions by redefining the treatment experience and providing innovative solutions